

Clinical trials of troglitazone

TrialResults-center www.trialresultscenter.org

1 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
troglitazone vs placebo			
TRIPOD (Buchanan) , 2002 n=133/133 follow-up: 30 months (median)	troglitazone 400 mg once daily versus placebo	Hispanic women with previous gestational diabetes	Parallel groups double blind USA
US DDP troglitazone (Knowler) , 2005 n=585/582 follow-up: 0.9 year	troglitazone versus double placebo	nondiabetic patients with elevated glucose and high risk for diabetes	Parallel groups double blind USA

└ More details and results :

- prevention for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q341>
- prevention for diabetes type 2 in people with impaired glucose tolerance at <http://www.trialresultscenter.org/go-Q416>

References

TRIPOD (Buchanan), 2002:

Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002;51:2796-803 [[12196473](#)]

US DDP troglitazone (Knowler), 2005:

Knowler WC, Hamman RF, Edelstein SL, Barrett-Connor E, Ehrmann DA, Walker EA, Fowler SE, Nathan DM, Kahn SE Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005;54:1150-6 [[15793255](#)]